New Home For OTC Drug Review Would Restore Momentum – Hutt, Yingling

“By your actions you have shown you don’t want the review to be completed,” former FDA chief counsel Peter Barton Hutt tells agency officials at a public hearing. Hutt and former agency attorney Gary Yingling suggest FDA move the OTC drug review out of CDER’s Office of New Drugs.